Sarepta shares drop as report says FDA almost rejected under-review gene therapy

[cafead]

via Sarepta Therapeutics Inc's shares fell as much as 19.4% premarket on Thursday as Stat News reported that the U.S. Food and Drug Administration's staff were inclined to reject the company's gene therapy which is currently under review.

article source